Guillaume Dureau of Orano Group (left) and Orano Med’s Julien Dodet cut the ribbon on the new ATLabs Indianapolis. (Photo: Orano)

Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated its first ATLab (Alpha Therapy Laboratory) earlier this month. Located in Brownsburg, near Indianapolis, Ind., ATLab Indianapolis is an industrial-scale pharmaceutical facility dedicated to the production of lead-212–based radioligand therapies.

Targeted alpha therapy has shown to be effective in treating various oncological diseases, combining the natural ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha emissions generated by Pb-212. With a half-life of 10.64 hours, along with a decay product of the short-lived alpha-emitter bismuth-212, Pb-212 allows for the possible synthesis and purification of complex radiopharmaceuticals with minimum loss of radioactivity during preparation.

The development of radiopharmaceuticals has long been hampered by the difficulty of manufacturing and distribution on an industrial scale, Orano said, adding that the construction of ATLab Indianapolis is a major step toward making these new treatments available to cancer patients with high unmet needs in North America.

The American Nuclear Society’s Risk-informed, Performance-based Principles and Policy Committee (RP3C) held another Community of Practice (CoP) on April 26. For this event, the committee welcomed Mory Diané of Oklo. RP3C chair N. Prasad Kadambi led with a brief introduction before Diané shared Oklo's risk-informed, performance-based (RIPB) approach to seismic design categorization and seismic siting characterization.

Diané, a licensing manager with Oklo, is a structural engineer with a background in civil engineering

Framatome and Korea Hydro & Nuclear Power (KHNP) have announced the signing of a memorandum of understanding to explore the possibility of producing the medical isotope lutetium-177 at KHNP’s Wolsong nuclear power plant in South Korea. The companies also will investigate the feasibility of using the plant to support Korean production of medical radioisotopes in the future.

According to the Council on Radionuclides and Radiopharmaceuticals, more than 82,000 nuclear imaging procedures using nuclear medicine are performed throughout the world every day. To administer these vital medical procedures, radiopharmaceutical companies and hospitals rely on a handful of producers of medical radioisotopes.

Radiopharmaceutical biotech company ITM Isotope Technologies Munich announced it has received regulatory approval to begin production of the medical radioisotope lutetium-177 at the company’s NOVA facility in Neufahrn, near Munich, Germany.

Framatome and Nuclearelectrica, operator of Romania’s Cernavoda nuclear power plant, announced the signing of a memorandum of understanding to explore the possibility of producing the medical isotope lutetium-177. The cooperative agreement was signed during the World Nuclear Exhibition 2023, held November 28–30 in Paris.

Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.

BWX Technologies subsidiary BWXT Medical has agreed to provide Fusion Pharmaceuticals with generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.

German-based radiopharmaceutical biotech company ITM Isotope Technologies Munich and Canadian Nuclear Laboratories are launching a new joint venture company for the industrial-scale production of actinium-225, which is used in targeted alpha therapies to fight cancer. The new company is being called Actineer.

Bruce Power, the utility in Ontario, Canada, and health-care company Nordion announced that they are working to increase the production of cobalt-60 to meet increasing world market demands. The companies said they will increase the amount of Co-60 Bruce Power is able to produce in its reactors “by innovating a new adjuster component configuration.”

Fusion tech company SHINE Technologies announced that it is opening the largest facility in North America dedicated to the production of non-carrier-added lutetium-177, a medical isotope used in targeted cancer therapies.

The University of Missouri intends to build a new, larger research reactor to produce medical radioisotopes, announcing that it intends to issue a request for qualification/request for proposal (RFQ/RFP) in April to solicit interest from qualified parties to provide preliminary designs and industry partnerships for the new reactor project, called NextGen MURR.

One of the biggest challenges in the nuclear community identified by ANS in 2017 is the continuous availability of radioisotopes. Working to meet that challenge is the ANS-led Source Security Working Group (SSWG), an alliance of industry sectors—including energy, health care, and industrial radiography—that seeks to ensure continued access to radiological sources. The SSWG serves as a strong voice to protect the continued availability of radiological sources, ensuring that laws and policies are risk informed, science based, and support the highest levels of public health and safety.

The Nuclear Regulatory Commission has issued the final supplemental environmental impact statement (EIS) for SHINE Technology’s application for a license to operate a medical isotope production facility in Janesville, Wis.

In a former farm field just outside the historic town of Janesville in south-central Wisconsin, a large concrete-and-steel building is taking shape. Dubbed the Chrysalis, the building will eventually house eight accelerator-based neutron generators, which start-up company SHINE Technologies will use to produce molybdenum-99. As the precursor to the medical radioisotope technetium-99m, Mo-99 is used in tens of millions of diagnostic procedures every year, primarily as a radioactive tracer.

At the heart of the Chrysalis will be the high-flux neutron generators, being supplied by SHINE’s sister company, Phoenix. The compact accelerators use a deuterium-tritium fusion process to produce neutrons, which in turn induce a subcritical fission reaction in an aqueous low-enriched uranium target (19.75 percent uranium-235) to produce Mo-99.

An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM) announced they have begun commercial production of lutetium-177 using Unit 7 of the Bruce nuclear power plant in Kincardine, Ontario. According to the companies, this marks the first time a commercial power reactor has been used to commercially produce short-lived medical radioisotopes.

SHINE Europe, a subsidiary of Wisconsin-based SHINE Technologies, will work with the Netherlands’ University Medical Center Groningen (UMCG) and Delft University of Technology (TU Delft) to produce a variety of terbium isotopes for use in nuclear medicine under a grant proposal approved by the Dutch government on October 17.

SHINE Technologies, the Janesville, Wis.–based producer of medical radioisotopes, announced that it has submitted a drug master file (DMF) with the U.S. Food and Drug Administration for non-carrier-added (n.c.a.) lutetium-177 chloride, a radiopharmaceutical used for the treatment of cancer.

The Nuclear Regulatory Commission is holding a virtual event and teleconference on SHINE Medical Technologies’ plans to license and operate a medical isotope production facility in Janesville, Wis. The online public meeting will be held on July 27 from 7:00 p.m. to 9 p.m. (EDT).

The NRC is also seeking the public’s views regarding the agency’s draft supplemental environmental impact statement for SHINE’s application for a license to operate the facility, particularly regarding the conclusion that the environmental impacts are not great enough to prevent the NRC from considering issuance of the license.

An international collaboration between Bruce Power, Isogen (a joint venture of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE, announced a milestone marking the first time that lutetium-177, a short-lived medical radioisotope, has been produced in a commercial nuclear power reactor.